ArticleJournal of psychopharmacology (Oxford, England)2023
The New Zealand drug harms ranking study: A multi-criteria decision analysis.
Article in Journal of psychopharmacology (Oxford, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Assessment of drug harm by final-year medical students and ChatGPT - a comparative analysis.Substance abuse treatment, prevention, and policy · 2026Article
- Impact of cannabis, benzodiazepines, and methamphetamine use on inflammatory and hepatic biomarkers in Benin City, Nigeria: a case-control study.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Adapting multi-criteria decision analysis of drug harms to reflect population-level health outcomes: An innovation in public health policy.Canadian journal of public health = Revue canadienne de sante publique · 2026Article
- Alcohol Marketing Exposure to Children in New Zealand: A Systematic Narrative Review.Journal of the Royal Society of New Zealand · 2026Review
- Drug harms in Canada: A multi-criteria decision analysis.Journal of psychopharmacology (Oxford, England) · 2026Article
- Level of preparedness to use psilocybin among individuals seeking psychedelic risk reduction: a retrospective study of a pilot psychiatric consultation service.Frontiers in public health · 2026Article
- US drug policy does not align with experts' rankings of drug harms: a multi-criteria decision analysis.Harm reduction journal · 2025Article
- Tū Whakaruruhau: the evaluation of treatment outcomes for methamphetamine dependence in Aotearoa, New Zealand - study protocol for a prospective longitudinal cohort study and longitudinal qualitative study.BMC health services research · 2025Article
- Assessment of suicidal risk factors in young depressed persons with non-suicidal self-injury based on an artificial intelligence.BMC psychology · 2025Article
- DSM-5 Criteria for Alcohol and Cannabis Use Disorders: Are Older Adults Less Likely to Endorse Certain Criteria?International journal of environmental research and public health · 2025Article
- Rising transphobia and disparities in drug-related harm experienced by transgender and gender-diverse people.Harm reduction journal · 2025Review
- Dynamic regulation of CeA gene expression during acute and protracted abstinence from chronic binge drinking of male and female C57BL/6J mice.Alcohol (Fayetteville, N.Y.) · 2024Article
- Perceived Risk of Binge Drinking among Older Alcohol Users: Associations with Alcohol Use Frequency, Binge Drinking, Alcohol Use Disorder, and Alcohol Treatment Use.International journal of environmental research and public health · 2024Article
- Perception is reality: qualitative insights into how consumers perceive alcohol warning labels.Alcohol and alcoholism (Oxford, Oxfordshire) · 2024Article
- A thematic analysis of MDMA-related harm and harm reduction experiences and knowledge in Aotearoa New Zealand.Harm reduction journal · 2024Article
- Harm reduction behaviours and harm experiences of people who use 3,4-methylenedioxymethamphetamine (MDMA) in Aotearoa New Zealand.Harm reduction journal · 2024Article
- Dynamic regulation of CeA gene expression during acute and protracted abstinence from chronic binge drinking of male and female C57BL/6J mice.bioRxiv : the preprint server for biology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThe harms arising from psychoactive drug use are complex, and harm reduction strategies should be informed by a detailed understanding of the extent and nature of that harm. Drug harm is also context specific, and so any comprehensive assessment of drug harm should be relevant to the characteristics of the population in question. This study aimed to evaluate and rank drug harms within Aotearoa New Zealand using a multi-criteria decision analysis (MCDA) framework, and to separately consider harm within the total population, and among youth.
methodsTwo facilitated workshops involved the separate ranking of harm for the total population, and then for youth aged 12-17, by two expert panels. In the total population workshop, 23 drugs were scored against 17 harm criteria, and those criteria were then evaluated using a swing weighting process. Scoring and weighting were subsequently updated during the youth-specific workshop. All results were recorded and analysed using specialised MCDA software.
resultsWhen considering overall harm, the MCDA modelling results indicated that alcohol, methamphetamine and synthetic cannabinoids were the most harmful to both the overall population and the youth, followed by tobacco in the total population. Alcohol remained the most harmful drug for the total population when separately considering harm to those who use it, and harm to others.
conclusionsThe results provide detailed and context-specific insight into the harm associated with psychoactive drugs use within Aotearoa New Zealand. The findings also demonstrate the value of separately considering harm for different countries, and for different population subgroups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.